ArticlePharmacoEconomics2005

Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.

Peter K Schädlich et al.PubMed ↗Publisher ↗

No numbers read from the abstract.